FIELD: medicine.
SUBSTANCE: group of inventions relates to the treatment of multifocal prostate cancer. Disclosed is the use of fexapotide triflutate (FT) in a method for reducing the incidence of multifocal cancer, reducing the degree of cancer and reducing the progression (deterioration) of cancer in the whole prostate gland of mammals suffering from single-focal prostate cancer, where the method involves detecting a mammal with a single-focal prostate cancer; and administering to a mammal a composition comprising fexapotide triflutate (FT) by injection directly into a single-focal prostate cancer. Also disclosed is a method for reducing the incidence of multifocal prostate cancer, reducing the degree of prostate cancer and reducing the progression (deterioration) of prostate cancer in a mammal with single-focal prostate cancer.
EFFECT: group of inventions provides reducing the incidence of multifocal cancer, the degree of cancer and the progression of cancer.
9 cl, 10 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR PREDICTING PROSTATE CANCER | 2016 |
|
RU2760577C2 |
| METHOD FOR INDUCING SELECTIVE DRUG ABLATION OF THE PROSTATE GLAND WITHOUT NERVE DAMAGE, WHILE PRESERVING THE SEXUAL FUNCTION | 2019 |
|
RU2776047C1 |
| PATIENT SELECTION METHOD FOR ULTRASOUND HEMIABLATION OF LOCALIZED PROSTATE CANCER | 2017 |
|
RU2676599C1 |
| PHOSPHODIESTERASE 4D7 AS MARKER FOR AGGRESSIVE HORMONE-SENSITIVE PROSTATE CANCER | 2010 |
|
RU2575076C2 |
| METHOD OF BRACHYTHERAPY FOR LOCALISED PROSTATE CANCER | 2015 |
|
RU2606108C2 |
| METHODS OF TREATING ONCOLOGICAL DISEASES | 2011 |
|
RU2589513C2 |
| METHOD OF ANTITUMOUR IMMUNOTHERAPY | 2012 |
|
RU2530523C2 |
| USE OF PEPTIDE OF NERVOUS THREADS FOR PREVENTING OR REDUCING PROGRESSION OF PROSTATE CANCER | 2017 |
|
RU2719598C1 |
| METHOD FOR DETECTING SOLID MALIGNANT TUMOR | 2015 |
|
RU2720148C2 |
| METHOD FOR PREDICTION OF AGGRESSIVE FORMS OF PROSTATE CANCER IN PATIENTS OF INTERMEDIATE AND HIGH RISK GROUP | 2021 |
|
RU2768477C1 |
